References
- Ferro A. Paediatric prescribing: why children are not small adults. Br J Clin Pharmacol. 2015;79(3):351–353.
- Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. Br J Clin Pharmacol. 2015;79(3):357–369.
- Ungar WJ. Economic evaluation in child health. Oxford: Oxford University Press; 2010.
- Allegaert K. Tailored tools to improve pharmacotherapy in infants. Expert Opin Drug Metab Toxicol. 2014;10(8):1069–1078.
- Stiers JL, Ward RM. Newborns, one of the last therapeutic orphans to be adopted. JAMA Pediatr. 2014;168(2):106–108.
- Turner MA. Clinical trials of medicines in neonates: the influence of ethical and practical issues on design and conduct. Br J Clin Pharmacol. 2015;79(3):370–378.
- Shirkey H. Conference of professional and scientific societies. Chicago (IL): Commission on Drug Safety; 1963.
- Adlard N, Kinghorn P, Frew E. Is the UK NICE “reference case” influencing the practice of pediatric quality-adjusted life-year measurement within economic evaluations? Value Health. 2014;17(4):454–461.
- Ungar WJ, Prosser LA, Burnett HF. Values and evidence colliding: health technology assessment in child health. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):417–419.
- Stevens K. Valuation of the child health utility 9D index. Pharmacoeconomics. 2012;30(8):729–747.
- Stevens AJ, Longson C. At the center of health care policy making: the use of health technology assessment at NICE. Med Decis Making. 2013;33(3):320–324.
- Wille N, Badia X, Bonsel G, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res. 2010;19(6):875–886.
- Stevens KJ. Working with children to develop dimensions for a preference-based, generic, pediatric, health-related quality-of-life measure. Qual Health Res. 2010;20(3):340–351.
- van Reenen M, Janssen B, Oppe M, et al. EQ-5D-Y user guide (version 1.0). Rotterdam: EuroQol Research Foundation; 2014.
- Craig BM, Greiner W, Brown DS, et al. Valuation of child health-related quality of life in the United States. Health Econ. 2016;25(6):768–777. doi:10.1002/hec.3184
- Ratcliffe J, Stevens K, Flynn T, et al. Whose values in health? An empirical comparison of the application of adolescent and adult values for the CHU-9D and AQOL-6D in the Australian adolescent general population. Value Health. 2012;15(5):730–736.
- Craig BM, Brown DS, Reeve BB. The value adults place on child health and functional status. Value Health. 2015;18(4):449–456.
- Chen G, Ratcliffe J. A review of the development and application of generic multi-attribute utility instruments for paediatric populations. Pharmacoeconomics. 2015;33(10):1013–1028.
- NICE. TA13: methylphenidate for the treatment of attention deficit hyperactivity disorder in children and adolescents. 2000. [cited 2015 Aug 28]. Available from: https://www.nice.org.uk/guidance/ta13.
- NICE. TA98: methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. 2006. [cited 2015 Aug 28]. Available from: https://www.nice.org.uk/guidance/ta98.
- NICE. TA292: aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder. 2013. [cited 2015 Aug 28]. Available from: https://www.nice.org.uk/guidance/ta292.
- NICE. TA187: infliximab (review) and adalimumab for the treatment of Crohn’s disease. 2010. [cited 2015 Aug 28]. Available from: https://www.nice.org.uk/guidance/ta187.